- Home
- SOUNW vs ERNAW Comparison
SOUNW vs ERNAW Comparison
Compare SOUNW & ERNAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOUNW | ERNAW |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | 842 | 6 |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SOUNW | ERNAW |
|---|---|---|
| Price | $2.50 | $0.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 24.5K | ★ 28.3K |
| Earning Date | 02-27-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,297,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 76.05 | N/A |
| 52 Week Low | $2.27 | $0.05 |
| 52 Week High | $10.82 | $0.11 |
Technical Indicators
Market Signals| Indicator | SOUNW | ERNAW |
|---|---|---|
| Relative Strength Index (RSI) | 38.34 | 52.47 |
| Support Level | $2.43 | $0.06 |
| Resistance Level | $3.59 | $0.10 |
| Average True Range (ATR) | 0.30 | 0.01 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 4.07 | 46.43 |
Price Performance
Historical ComparisonAbout SOUNW SoundHound AI Inc. Warrant
SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers. The company's voice AI delivers speed and accuracy in numerous languages to product creators and service providers across retail, financial services, healthcare, automotive, smart devices, and restaurants via groundbreaking AI-driven products like Smart Answering, Smart Ordering, Dynamic Drive-Thru, and Amelia AI Agents.
About ERNAW Ernexa Therapeutics Inc. Warrants
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.